Monitoring and Managing Adverse Events in Older Adults with MDS
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: May 31, 2017
Expiration Date: May 31, 2018
Expected time to complete this activity as designed: 45 minutes
There are no fees for participating in or receiving credit for this online activity.
Treatment selection is critical in older patients with myelodysplastic syndromes (MDS) who have an increased risk for experiencing treatment-emergent adverse events (TEAEs) and require tailored monitoring parameters and strategies for managing associated toxicities. In this activity, Dr. Gore will address the efficacy data of currently available therapies that must be considered in the selection of therapeutic regimens, as well as the major adverse events associated with each, and toxicities of notable concern in older patients with MDS. Managing TEAEs in older patients with significant comorbidities may reduce the potential for premature discontinuation of an otherwise effective therapy, allowing the patient maximum treatment benefit.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in myelodysplastic syndromes.
Upon completion of this educational activity, participants should be able to:
- Describe the safety and efficacy profile of the currently available therapies for patients with MDS
- Recognize the TEAEs of greatest concern in older patients with MDS
Monitoring and Managing Adverse Events in Older Adults with MDS – Steven D. Gore, MD
Instructions for Participation and Credit
This activity is eligible for credit through May 31, 2018. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Steven D. Gore, MD
Professor of Internal Medicine, Section of Hematology
Director of Hematologic Malignancies
Yale Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut
Dr. Steven Gore has been a leader in drug development in myeloid malignancies, focusing on the optimization of putatively epigenetically targeted agents, and understanding of their mechanism of action. He served on the oncology faculty at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in the Division of Hematologic Malignancies from 1990 through 2013. Since 2013 he has directed Hematologic Malignancies at the Yale Cancer Center and Smilow Cancer Hospital. He serves on the NCI Leukemia Steering Committee and is co-chair of the National Heart, Lung, and Blood Institute (NHLBI) Myelodysplastic Syndromes (MDS) Natural History Study.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-138-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Steven Gore has received honoraria as a consultant from Boehringer Ingelheim GmbH, Celgene Corporation, and Kyowa Kirin Pharmaceutical Development, Inc. He has received grant support related to research activities from Boehringer Ingelheim and Celgene.
Planning Committee Disclosures
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.